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Neutrophil-activating peptide-2 (NAP-2) is a 70-residue
carboxyl-terminal fragment of platelet basic protein,
which is found in the a-granules of human platelets.
NAP-2, which belongs to the CXC family of chemokines
that includes Interleukin-B and platelet factor 4, binds to
the interleukin-8 type II receptor and induces a rise in
cytosolic calcium, chemotaxis of neutrophils, and exocy-
tosis. Crystals of recombinant NAP-2 in which the single
methionine at position 6 was replaced by leucine to facil-
itate expression belong to space group PI (unit cell pa-
rameters a = 40.8, b = 43.8, and c = 44.7 A and a = 98.4°, fl
= 120.3°, and 'Y = 92.8°), with 4 molecules of NAP-2 (Mr =
7600) in the asymmetric unit. The molecular replacement
solution calculated with bovine platelet factor 4 as the
starting model was refined using rigid body refinement,
manual fitting in solvent-leveled electron density maps,
simulated annealing, and restrained least squares to an
R-factor of 0.188 for 2 fT data between 7.0- and 1.9-A reso-
lution. The final refined crystal structure includes 265
solvent molecules. The overall tertiary structure, which is
similar to that of platelet factor 4 and interleukin-8, in-
cludes an extended amino-terminal loop, three strands of
antiparallel fl-sheet arranged in a Greek key fold, and one
a-helix at the carboxyl terminus. The Ghr-Leu-Arg se-
quence that is critical for receptor binding is fully defined
by electron density and exhibits multiple conformations.
Neutrophil-activating peptide-2 (NAP-2)1 is a cleavage prod-
uct of the platelet a-granule component, platelet basic protein
(PBP) and its derivative, connective tissue-activating peptide
III (CTAP-IID (Castor et al., 1983; Walz and Baggiolini, 1990).
NAP-2 corresponds to the carboxyl-terminal fragment of PBP,
which is cleaved by monocyte-derived proteases, and gives rise
to a single peptide of 70 amino acids with a M; of 7600 (Walz
and Baggiolini, 1989). CTAP-II1 and fl-thromboglobulin ({3-TG),
an additional truncation product of PBP (Begg et al., 1978), can
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1 The abbreviations used are: NAP-2, neutrophil-activating pep-
tide-2; PBP, platelet basic protein; CTAP, connective tissue-activating
peptide; I3-TG, l3-thromboglobulin; PF4, platelet factor 4; IL-8, interleu-
kin-8; GRO,growth-related protein; yIP-10,interferon-v-inducible pep-
tide-l0; HPLC, high pressure liquid chromatography.
also be cleaved by neutrophil cathepsin G to generate NAP-2
(Cohen et al., 1992).
Members of the chemotactic cytokine family, which are col-
lectively known as chemokines, have four conserved cysteine
residues and are divided into two subfamilies according to the
position of the first pair of cysteines, which are separated by
one amino acid (CXC) or are adjacent (CC) (Baggiolini et al.,
1994; Baggiolini and Clark-Lewis, 1992). The members of the
two subfamilies differ in their selectivity, with the CXC sub-
family targeting neutrophils and the CC subfamily targeting
monocytes (Baggiolini et al., 1994). PBP and its successive
cleavage products, CTAP-IlI, {3-TG, and NAP-2, belong to the
CXC subfamily. Other members of this CXC subfamily include
platelet factor 4 (PF4) (Deuel et al., 1977; Hermodson et al.,
1977); interleukin-8 (IL-8) (Sherry and Cerami, 1991; Baggio-
lini and Clark-Lewis, 1992); the growth-related proteins
GROa, GRO{3, and GRO-y(Haskill et al., 1990; Tekamp-Olson et
al., 1990); ENA-78, a neutrophil-activating peptide identified
in the conditioned medium of stimulated human type II epi-
thelial cell line A549 (Walz et al., 1991); macrophage inflam-
matory protein-2 (Wolpe et al., 1988); and interferon-v-induci-
ble peptide-l0 (-yIP-I0) (Luster et al., 1985).
Unlike its three natural precursors, PBP, CTAP-IlI, and
,B-TG, NAP-2 has powerful neutrophil-stimulating effects in-
volved in inflammation (Walz et al., 1989). NAP-2 behaves as a
typical chemotactic receptor agonist, inducing a rise in cytosolic
calcium, chemotaxis, and exocytosis at concentrations between
0.3 and 10 nM. NAP-2, which is approximately half as potent as
IL-8 as a neutrophil activator (Walz et al., 1989 J, is released
mainly into the vasculature where platelet activation and ag-
gregation occur, whereas IL-8 is formed within tissues. IL-8,
NAP-2, GROa, and ENA-78 bind to common receptors on neu-
trophils (Walz et al., 1989, 1991; Moser et al., 1990, 1991) and
share a highly conserved Glu-Leu-Arg (ELR) sequence at their
amino-terminal end that has been shown to be critical for
receptor binding (Hebert et al., 1991; Clark-Lewis et al., 1991;
Moser et al., 1993). Comparable neutrophil responses were not
observed with PF4 (Walz et al., 1989; Lenord et al., 1991),
although chemotaxis and exocytosis have been reported with
concentrations that were 1000-1O,000-fold higher than those
required for IL-8 (Deuel et al., 1981; Bebawy et al., 1986; Park
et al., 1990). No neutrophil-stimulating or other biological ac-
tivities have been observed with -yIP-I0 (Dewald et al., 1992).
Recent experiments have suggested that post-translationally
modified forms of CTAP-lII and NAP-2 can function as endoglu-
cosamidases that degrade heparin and heparan sulfate to dimers
(Hoogewerf et al., 1993). Chondroitin and dermatan sulfates are
not cleaved. This discovery further suggests a possible role for
NAP-2 in the breakdown of basement membranes that occurs
during metastasis, angiogenesis, and arthritis.
No other structure ofNAP-2 is available, although the crys-
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tallization of recombinant NAP-2 was recently reported (Kungl
et al., 1994). However, crystal structures of bovine PF4 (St.
Charles et al., 1989), IL-8 (Baldwin et al., 1991), and recombi-
nant human PF4 (Stuckey, 1992; Zhang et al., 1994) have been
elucidated. The structure of IL-8 has been determined by NMR
methods as well (Clore et al., 1990). In all cases, the secondary
structure of the monomer consists of an extended loop, three
strands of antiparallel f3-sheet folded in a Greek key, and one
a-helix at the carboxyl terminus ofthe protein. In solution, IL-8
exists as a dimer in which the two monomers form an extended
six-stranded f3-sheet (Clore et al., 1990). In the crystal struc-
ture of IL-8, the dimer lies on a crystallographic two fold so
there is only a monomer in the asymmetric unit. PF4, which
exists primarily as a tetramer in solution, formed orthorhombic
crystals with a tetramer in the asymmetric unit that was
formed by the back-to-back association of the extended f3-sheets
of two dimers (St. Charles et al., 1989). In this paper, we
present a refined crystal structure of biologically active, recom-
binant human NAP-2 IM6L}2 in which methionine at position 6
in the NAP-2 sequence has been replaced by leucine to facili-
tate expression (Castor et al., 1990). The crystal structure
contains a PF4-like tetramer in the asymmetric unit of the
triclinic unit cell.
MATERIALS AND METHODS
Preparation of Recombinant NAP-2-Escherichia coli cells were
transformed with the pBR-CRM-CTAP-Met20,Leu26 {M15,L21} plas-
mid, which coded for a modified form of CTAP-III that had Met-20
replacing tyrosine and Leu-26 replacing methionine (Waleh et al.,
1992). Cleavage at Met-20 in CTAP-III with CNBr generates the amino
terminus of native NAP-2, while the M26L substitution prevents the
generation of a truncated form ofNAP-2. Transformed E. coli cells were
grown in shaker flasks in Luria broth containing 50 fLg/ml ampicillin at
37°C. CTAP (Met-20,Leu-26) protein expression was induced at anA6 6 0
of 0.4 by the addition of mitomycin C to a final concentration of 1 fLg/ml.
Cells were harvested and lysed by suspension in 6 Mguanidine HCI, 0.1
M Tris-HCI (pH 8.0), 10 mM EDTA, and 6 mM sodium thiosulfate to
protect against oxidation of cysteine by CNBr. The solution was purged
with argon to remove oxygen, adjusted to 0.2 Min phosphoric acid and
to 0.2 Min cyanogen bromide, and incubated overnight in the dark at
room temperature. Besides generating free NAP-2 (M6LI, this treat-
ment also aided in subsequent purification steps by fragmenting the
endogenous E. coli proteins. The reaction mixture was dialyzed against
deionized water to remove salts, CNBr, and sodium thiosulfate and
freeze-dried.
The protein powder was dissolved and incubated for 1 h at 37°C in
6 Mguanidine HCI, 10 mM EDTA, 0.1 Mdithiothreitol, 25 mMTris-HCI
(pH 8.6) to reduce disulfide bonds and to remove sulfonate-protecting
groups from cysteine sulfhydryls. The solution was prepared for
reverse-phase HPLC by acidification with 0.02 volumes of 88% formic
acid, addition of 0.43 volumes of acetonitrile in 0.065% (v/v) trifluoro-
acetic acid, and centrifugation or filtration to remove any precipitate
that formed. The reduced NAP-2 was purified on a Vydac 214TP1520
L-inch diameter reverse-phase column using a gradient that increased
from 20% of eluant B to 35% at a rate of 0.1%/minute at a flow rate of
10 mllmin. Eluant A was water, and eluant B was acetonitrile (both
0.065% (v/v) in trifluoroacetic acid). The peak of reduced NAP-2 was
pooled and lyophilized. NAP-2 was refolded at a concentration of 0.2
mg/ml in 2 Mguanidine HCI, 0.1 MTris-HCI (pH 8.6), 10 mM EDTA, 2
mMoxidized glutathione, 1 mMreduced glutathione at 37°C for 2 h. The
solution was acidified by the addition of 0.02 volumes of88% formic acid
and 0.33 volumes of acetonitrile. The filtered refolded NAP-2 was pu-
rified on a Vydac 214TP1022 high-resolution reversed-phase column
2 The residues of NAP-2 and the other chemokines are identified in
the text by the three-letter code for amino acids and the equivalent
position ofthe residue in the sequence of bovine platelet factor 4 (Fig. 1).
Where appropriate, residues are also identified between braces by the
one-letter code and the position of the residue in its own sequence. By
this convention, the 70 residues in NAP-2 extend from Ala-21 (AI) to
Asp-90 (D70}. We use residue positions 21-90 when speaking generally
of all four subunits. Specific residues in the separate subunits of the
NAP-2 tetramer are distinguished by subscripts, for example, sequence
numbers 218-908 for subunit A.
using the same gradient as described above. The NAP-2 peak was
pooled and freeze-dried. Purity was judged to be >98% as assessed by
spectral and amino acid composition analyses, amino-terminal sequenc-
ing, and analytical HPLC. Typical yields were 20-30 mg/liter of induced
culture.
Crystallizotion-s-Cryeuu« were grown by the hanging drop method at
22°C from reservoirs containing 28% polyethylene glycol 4000, 100 mx
sodium acetate (pH 4.6), and 200 mM ammonium acetate. The initial
concentration of NAP-2 in the drop was 17 mg/ml. The crystals belong
to space group PI with unit cell dimensions of a = 40.8, b = 43.8, and
c = 44.7 A and a = 98.4°, f3 = 120.3°, and y = 92.8°, with four monomers
in the asymmetric unit.
Data Collection-Diffraction data were collected at 22°C on a single
crystal (0.40 x 0.20 x 0.20 mm) mounted in a quartz capillary. The
Siemens X-lOOO area detector was mounted on a Rigaku RU200H
rotating anode x-ray generator (CuKa radiation) that was operated at
40 kV and 70 rnA and equipped with a Supper graphite monochromator.
The data collection, which was organized using the program ASTRO
(Chambers et al., 1992), was done in eight sweeps of 280 frames/sweep
at 0.25°/frame. Each frame was collected for 3 min to ensure that it
contained at least one million total counts. The data were merged and
scaled using the program XENGEN (Howard et al., 1987), yielding
30,511 reflections, 17,830 of which were unique between 7.0 and 1.9 A.
These data, which represent 86.7% of the possible reflections, had an
overall unweighted absolute R sy m of 0.025 based on intensities. For the
three shells, 7.0 to 2.1, 2.1 to 2.0, and 2.0 to 1.9 A, the completeness
percentages were 97, 85, and 47%, respectively.
Molecular Replacement-The structure was solved by the molecular
replacement method (Rossman and Blow, 1962) using the XPLOR suite
of programs (Brunger, 1988) with a previously determined structure of
PF4 as the model (St. Charles et al., 1989). Because the sequence
identity between the model and NAP-2 is 50%, residues that were not
identical between structures were changed to alanine. The model tet-
ramer was then placed in a 1Oo-API orthogonal unit cell with its center
of mass placed at the origin. The cross-rotation function was calculated
for the range li l = 0-360°, li2 = 0-180°, and li" = 0-360° (Rao et al.,
1980) using the data between 7.0 and 4.0 A. Patterson correlation
refinement (Brunger, 1988) of the 150 most significant solutions iden-
tified two rotations, related by 179.5°, whose coefficients were above
0.43; the third best rotation had a correlation coefficient of 0.35. The
first rotation (lil = 297.2°, li2 = 13.9°, and li" = 40.4°) was used to orient
the model in the crystallographic unit cell. For convenience, the model
was translated by x = 0.5, y = 0.5, and z = 0.5, so that roughly one
tetramer would be contained within the limits of the unit cell. No
translation function was calculated because there is only one tetramer
in the PI unit cell. The initial R-factor was 0.539 for data from 7.0- to
3.0-A resolution.
Structural Analysis-The coordinates for the crystal structure of
human IL-8 (entry 3IL8) and for the NMR structure ofIL-8 (entry lIL8)
were obtained from the Protein Data Bank (Bernstein et al., 1977). The
coordinates for bovine PF4 were obtained from those of St. Charles et al.
(1989) by refinement against diffraction data collected to 2.2-A resolu-
tion from crystals of bovine PF4 that were free of nickel tetracyanate
ions (Stuckey, 1992). The R-factor is 0.20. The coordinates for human
PF4 were obtained by molecular replacement using the bovine coordi-
nates and subsequent refinement to an R-factor of 0.19 at 2.0-A reso-
lution (Stuckey, 1992). Subunit B in NAP-2 was taken as the reference
structure because its amino terminus has the fewest crystal contacts.
Hydrogen bonds and surface accessibility values were calculated using
the program QUANTA (Polygen Corp., Waltham, MA). The criteria for
a hydrogen bond are that the angles C=O .. , H, O .. , H-N, and
H-N-C be greater than 90°C and the distance N ... 0 not exceed 3.3
A for a "short" hydrogen bond and 4.0 A for a "long" one (Baker and
Hubbard, 1984). Superposition of coordinates between structures was
done using the program ALIGN (Satow et al., 1986). Omit maps were
calculated in XPLOR.
RESULTS
Structure Solution and Refinement-After 200 cycles of rigid
body refinement, allowing the f3-sheet and helical domains to
refine independently, and fixing a different monomer in the
tetramer every 50 cycles, the R-factor fell to 0.47 for data from
7.0 to 3.0 A. Omit maps were calculated, in which a monomer
was deleted from the tetramer, to see that the density for the
deleted monomer was still present. Convinced that the solution
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FIG. 1. Sequence homology within the chemokine CXC subfamily. The sequences have been aligned to show the conservation of the four
cysteine residues. The sequence of NAP-2 is compared to other known proteins belonging to the CXC family, namely human lL-8 (Sherry and
Cerami, 1991; Baggiolini and Clark-Lewis, 1992), ENA-78 (Walz et al., 1991), GROa (Haskill et al., 1990; Tekamp-Olson et al., 1990), macrophage
inflammatory protein-2 (Wolpe et al., 1988), bovine (Ciaglowski et al., 1986) and human (Poncz et al., 1987) PF4, and yIP-10 (Luster et al., 1985).
The conserved ELR sequence and the 12 structurally conserved hydrophobic residues are boxed. The residue positions in PF4 are in boldface above
the sequences, and the corresponding numbers in IL-8 are given below.
was used to refine only the B values in each subunit. Twenty-
five cycles of B refinement dropped the R-factor to 0.188 for
data from 7.0 to 1.9 A and greater than 2 a.
The final refined model of the 4 molecules of NAP-2 in the
asymmetric unit (Fig. 2) has excellent stereochemistry when
evaluated with the program PROCHECK (Morris et al., 1992).
On the Ramachandran plot, 90.5% of the residues are in the
most favored region, and none lie in the disallowed region.
Other well refined structures at an equivalent resolution have
83.8% of their residues, on average, within the most favored
region. The nine other parameters evaluated by PROCHECK
simulated annealing utilizing the slow cool annealing protocol
in XPLOR. The dynamics temperature started out at 4000 K
and decreased in intervals of25 K to a final temperature of 0 K
with 25 steps (0.5 fs/step) ofVerlet dynamics at each temper-
ature. This reduced the R-factor to 0.328 using all the data
from 7.0 to 1.9 A. Side chains in subunit A that had been
replaced by alanine in the model were then placed into an
electron density map that was calculated with a locally written
program to perform noncrystallographic symmetry averaging."
Positional refinement and analysis of electron density maps
that were improved through solvent leveling, histogram match-
ing, and Sayre's equations using the program SQUASH
(Zhang, 1993) were then used to fit additional residues at the
amino and carboxyl termini of the individual subunits and to
adjust poorly fit side chains. The R-factor was reduced to 0.234
for all the data from 7.0 to 1.9 A.
At this point, all the residues were fit to well defined density
with the exception of the last four carboxyl-terminal residues in
each subunit and the three amino-terminal residues in subunit
C, which were disordered. These residues were removed before
proceeding with further refinement. Water molecules were
then added at positions that were within 2.5-3.5 Aof a hydro-
gen bonding donor or acceptor and had electron density in both
Fo - Fe and 2Fo - Fe maps. A total of 145 cycles of GPRLSA
refinement (Furey et al., 1982), including 265 water molecules,
dropped the R-factor to 0.202 for 2 a data from 7.0 to 1.9 A, with
root mean square deviations for bonds and wangles of 0.020 A
and 5.5°, respectively (Table I). Finally, the XPLOR program
3 P. Martin, unpublished data.
TABLE I
Refinement statistics from GPRLSA
Total no. of atoms
No. of solvent atoms
No. of observations
Mean isotropic B (A2)





915 peptide planes (A)
Chiral volume (A3)
Single torsion contacts (A)
Multiple torsion contacts (A)
Possible (X ... Y) H bond contacts (A)
Planar (00) torsion angles (degrees)
Staggered torsion angles (degrees)
Orthonormal torsion angles (degrees)
Final R-factor from GPRLSA
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FIG. 2. Structure ofNAP-2. Top, the a-carbon backbones of residues 21.-86. (thick lines) and of residues 21b-86b (thin lines) are shown in stereo.
The view is approximately down the AB noncrystallographic axis. Bottom, the a-carbon backbone of the NAP-2 tetramer is shown in stereo as
viewed approximately down the AD noncrystallographic axis. As drawn, subunits A (thick lines) and B (thin lines) are above subunits C (thin lines)
and D (thick lines).
are also equal to or better than the bounds established from
well refined structures at equivalent resolution.
Secondary Structure of NAP-2-The secondary structure of
NAP-2 is summarized in Fig. 3. The amino terminus, which
starts at position 21 in each subunit, is ordered in subunits A,
B, and D (Fig. 4), but Ala-21c, GIu-22 c, and Leu-23c are disor-
dered in subunit C. Ala-21 to Ile-34 form a large open loop that
is stabilized by the two disulfide bonds Cys-25-Cys-51 and
Cys-27-Cys-67. Also, there are bends, as defined by Kabsch
and Sander (1983), centered at residues 25 and 27 and one
hydrogen bond from Thr-31 to Cys-67. A main chain hydrogen
bond exists between the nitrogen of Asp-69 and the carbonyl
oxygen of Thr-31, which also contributes to stabilize the loop.
His-35 to Asn-38 form a single turn of 310 helix in an external
loop that is stabilized by main chain hydrogen bonds between
Asn-38 and His-35 and between Ile-39 and Pro-36.
The first strand of the three-stranded l3-sheet is formed by
Ile-39 to GIy-46. There are six main chain hydrogen bonds
formed with the adjacent subunit that form the extended six-
stranded l3-sheet (Fig. 3). GIu-43 a on the "interior side" of the
{3-sheet forms an internal salt bridge with Lys-Bfi, in the other
extended {3-sheet and similarly for the related pair GIu-43 c to
Lys-65 a . The respective Glu-OE2 to Lys-NZ distances are 2.61
and 3.31 A, respectively. The comparable salt bridges between
subunits Band D, namely Glu-43b-Lys-65d and GIu-43 d-Lys-
65b , which have Glu-OE2 to Lys-NZ distances of6.70 and 7.29
A, respectively, are not made due to the absence of perfect 222
symmetry in the crystal packing.
Lys-47 to Gin-53 form a hairpin loop (Sibanda and Thornton,
1985) between strands I and II of the {3-sheet. There is a
14-atom turn involving main chain hydrogen bonds formed
between the nitrogen of Gly-48 and the oxygen of Cys-51 and
between the nitrogen of Cys-51 and the oxygen of Gly-48.
Strands II and III of the {3-sheet are formed by Val-54 to Thr-59
and by Arg-64 to Leu-68, respectively. They are linked by
Leu-60 to GIy-63, which form a hydrogen-bonded type I reverse
turn. There are two {3-bulges(Richardson, 1981): a wide type at
Ile-39-Gln-40 and a G type at Gly-63-Arg-64.
Asp-69 to Arg-74 loop between strand III and the helix at the
end of the molecule. There is a hydrogen bond between Asp-69
and Ala-72 that forms an inverse y-turn (Rose et al., 1985).
Ile-75 to Asp-86 form an a-helix that lies diagonally across the
top of the l3-sheet.
Comparison of the 4 NAP2 Molecules-Although the 4 mol-
ecules of NAP-2 present in the asymmetric unit of our NAP-2
crystals are crystallographically independent and occupy non-
equivalent environments, they all have the 15-residue open
loop, three strands of antiparallel {3-sheet, and the 12-residue
helix lying across the pleated sheet as described above. The 4
molecules are paired to form two extended {3-pleated sheets of
six strands each (Fig. 2), which are then arranged back to back
to form a tetramer with approximate dimensions of 35 x 35 x
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45 A3. The subunits of the tetramer are related by quasi 222
symmetry. The two six-stranded f3-sheets that lie back to back
in the tetramer are bisected by a perpendicular rotation axis
that relates subunits A to B and subunits C to D with a rotation
angle of 178.5° (ALIGN). The two rotation axes parallel to the
FIG.3. Hydrogen bonds and topology of NAP-2. Main chain
hydrogen bonds for the four loops, three strands of J3-sheet, and one
a-helix found in the NAP-2 monomer are shown as arrows going from
the donor to the acceptor. The two disulfide bonds are indicated by thick
arrows. Ala-72 to Lys-81 in the helical region are also acceptors in
31Q-type hydrogen bonds with the residue three positions farther along
in the sequence. These hydrogen bonds are generally longer than the
a-helical type and are not shown. A hydrogen bond was included in the
diagram if it was present in all four subunits.
f3-sheets relate subunits A to C and subunits B to D with a
rotation angle of 179.4° and subunits A to D and subunits B to
C with a rotation angle of 170.1°.
The individual molecules are similar to one another as evi-
denced by the average root mean square deviation of 0.47 A in
C-a positions when they are overlapped in pairs (Table II). In
these six pairwise comparisons, the C-a atoms of 14 residues
(Ala-21 to Arg-24, l1e-28, Lys-29, His-35, Gly-48 to His-50, Asn-
52, and Ala-84 to Asp-86) were separated by more than twice the
average root mean square deviation in at least one of the over-
laps. The largest C-a deviations between the subunits (2.0-8.58
A) occur at the amino terminus where Ala-21a to Arg-24a interact
with residues in adjacent asymmetric units and consequently
exhibit a markedly different conformation from the same resi-
dues in subunits B and D (Fig. 5). Only five of the 14 residues,
namely Arg-24, Gly-48, Thr-49, Ala-84, and Asp-86, have C-a
deviations greater than 0.94 A that are not also associated with
differences in packing contacts with other subunits, either in the
same or adjacent asymmetric units. Among these five residues,
Thr-49, which is part of the loop between f3-strands I and II, has
the largest C-a displacement (2.18 Abetween subunits B and C)
and exceeds 0.94 A in all pairwise comparisons, except in the
overlap of subunits A and C.
DISCUSSION
The secondary structure and main chain hydrogen bonding
of NAP-2 as shown in Fig. 3 are very similar to those of the
other known structures in the CXC chemokine family (St.
Charles et al., 1989; Baldwin et al., 1991). Fig. 3 includes all of
the hydrogen bonds identified in an NMR analysis of the
f3-sheet region of NAP-2 (Yang et al., 1994) with the exception
of the bond between the nitrogen of Arg-64 and the oxygen of
Leu-60, which is a bond between the nitrogen of Gly-63 and the
oxygen of Leu-60 in the x-ray structure, as well as three f3-sheet
hydrogen bonds that are not detected by NMR, namely the two
bonds between l1e-45 and Glu-55 and the bond between the
nitrogen of l1e-57 and the oxygen of Glu-43.
Tertiary and Quaternary Interactions-In addition to the
disulfide and hydrogen bonds shown in Fig. 3, several clusters
of hydrophobic residues contribute to the integrity of the sub-
units. For example, l1e-34a and Pro-36a , which reside in the
loop structure, cluster with l1e-39a , Leu-42a , l1e-66a , and Leu-
68a in the f3-sheet and with Ile-75a and l1e-78a in the a-helix. At
the helix-sheet interface, Leu-42a and Val-56 a in the f3-sheet
contact Val-79a and the Coy, C-S, and C-e atoms of Lys-82 a .
Similarly, the dimer interface is strengthened by hydrophobic
contacts between residues in each helix, for instance Val-79 a ,
Lys-82 a (C-y, C-S, and C-e), and Leu-83a , and between residues
in the f3-sheet of the partner, Leu-42b , Val-44 b , and Val-56 b .
The overlap of the inner hydrophobic surfaces of the a-helices
with the f3-sheet strands from the adjacent monomer creates a
shallow hydrophobic groove between the helices that has a floor
FIG.4. Electron density for the ELK sequence of NAP-2. The electron density in a 2Fo - Fe map contoured at 2 a is shown in stereo for
Glu-22., Leu-23., and Arg-24. in NAP-2. The final refined model is shown in thick lines.
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defined by Leu-42a, Val-44a , Val-54a , and Val-56 a along with
the equivalent residues in subunit B and walls defined by
Pro-70a, Ile-75 a , Lys-76 a (side chain Coy, CoB, and C-E atoms),
Val-79a , and Leu-83 along with the same residues from subunit
B. The CD dimer has a similar groove.
The last four residues, Glu-87, Ser-88, Ala-89, and Asp-90,
are disordered in the electron density maps of NAP-2 {M6L\.
They are not part of the binding site for receptors (Clark-Lewis
et al., 1994), but when one to three of these residues are
removed, the activity of NAP-2 increases 4-fold (Brandt et al.,
1993). Possibly, these residues inhibit the activity of NAP-2,
which is most active as a monomer (Schnitzel et al., 1994), by
extending the a-helices farther across the adjacent f3-sheets
and thereby stabilizing the dimer interface.
TABLE II
Root mean square deviation of NAP-2 C-a coordinates from
those of other chemokines
NAP-2 Chemokine I3-Sheeta a-Helixb Overal1subunitls) subunitts)
A A A
NAP-2A NAP-2C 0.346 0.217 0.343
NAP-2A NAP-2D 0.434 0.206 0.499
NAP-2C NAP-2D 0.608 0.267 0.652
NAP-2Bc NAP-2A 0.376 0.216 0.438
NAP-2B NAP-2C 0.535 0.207 0.571
NAP-2B NAP-2D 0.307 0.254 0.304
NAP-2B PF4A (bovine)" 0.740 1.577 1.060
NAP-2B PF4A (human)" 0.998 1.666 1.175
NAP-2B IL-8 (x-ray) 1.113 0.328 0.939
NAP-2B IL-8A (NMR)d 1.077 0.639 1.305
NAP-2AB NAP-2CD 0.392 0.257 0.361
NAP-2AB PF4AB (bovine)" 1.033 1.689 1.327
NAP-2AB PF4AB (human)" 0.962 1.862 1.288
NAP-2AB IL-8AB (x-ray)" 1.919 1.760 2.112
NAP-2ABc IL-8AB (NMR) 1.431 3.248 2.254
a Residues 25-67.
b Residues 68-85.
c Subunit B was chosen as the reference structure because its amino
terminus was not involved in crystal contacts.
d Overlaps with the other subunits of the chemokine gave similar
values for the root mean square deviation.
e The IL-8 dimer (x-ray) was generated from crystallographic
symmetry.
The interface of the AB and CD dimers also is stabilized
through hydrophobic interactions. Leu-26a clusters with its
counterpart, Leu-26c, and also with Ile-57 c and the side chain
Coy, CoB, and C-E atoms of Lys-65 c. Ile-45 a in the f3-sheet also
interacts with the Coy, CoB, and C-Eatoms of Lys-Bfi., Similarly,
Leu-26b contacts Leu-26d• However, the interface between the
two dimers, which contains the four buried salt links discussed
earlier, appears to be predominantly hydrophilic in that 18 of
the 22 residues in the CD dimer that are within 3.5 A of a
residue in the AB dimer are hydrophilic.
Additional evidence for structural significance of the resi-
dues mentioned above comes from the similarity between the
specific residues in NAP-2 and residues in homologous proteins
within the chemokine family (Fig. 1). The potential for salt
links between Glu-43 a and Lys-Bfi, and between Lys-65 a and
Glu-43 c is conserved in bovine PF4, human PF4, and yIP-10,
while in IL-8, the acidic and basic residues have switched
positions, with lysine replaced by arginine at position 43. Also,
almost all of the hydrophobic residues mentioned above as
having important structural roles in NAP-2 occupy the same
positions throughout the chemokine family and are highly
conserved.
One exception occurs at position 26, where wild-type NAP-2
has methionine and other chemokines have valine, leucine,
threonine, or glutamine (Fig. 1). The hydrophobic contacts de-
scribed above for Leu-26 in our NAP-2 structure, which re-
places the wild-type methionine, suggest that a medium-sized
hydrophobic residue at this position shifts the dimer/tetramer
equilibrium toward tetramers. Human and bovine PF4, which
have Leu-26 and Val-26, respectively, form tetramers in the
crystal similar to those of our NAP-2 mutant and form mostly
tetramers in solution (Bock et al., 1980; Mayo and Chen, 1989),
whereas NAP-2 and IL-8, which have Met-26 and Gln-26, re-
spectively, exhibit a monomer/dimer/tetramer equilibrium in
solution (Schnitzel et al., 1994; Yang et al., 1994). At physio-
logical concentrations of 10-7 M and lower, both IL-8 and
NAP-2 exist and act primarily as monomers (Rajarathnam et
al., 1994; Schnitzel et al., 1994; Yang et al., 1994), although
protein cross-linking experiments indicate that IL-8 can also
bind as an oligomer to its receptor (Schnitzel et al., 1994). When
FIG.5. Conformation of the ELR sequence in the subunits ofNAP·2. The conformations of Ala-21, Glu-22, Leu-23, Arg-24, Cys-25, Leu-26,
and Cys-27 are compared for subunits A (thin lines) and B (thick lines). The conformation of Arg-.24b shown i~ solid li~es is the one mos~ similar
to that present in subunit D; the conformation shown in dashed lines is an alternative conformation present In subunit B only. In subunit C, the
first three residues are disordered, and the conformation of Arg-24 c is similar to that of Arg-24 b shown in solid lines. In subunit D, the four residues
have a conformation similar to that shown for subunit B.
Structure ofNeutrophil-activating Peptide-2 (M6L) 7083
FIG. 6. A model for the activation peptide of NAP-2. A helix is
predicted by the method of Holley and Karplus (1989) for Glu-12 to
Asp-16 in the activation peptide of {3-TG (Gly-l0 to Tyr-20). The acti-
vation peptide, which presents two negatively charged side chains on
one side of the helix, is shown bending back to interact with the ELR
region of NAP-2. The activation peptide is released from {3-TG to form
NAP-2 by cleavage between Tyr-20 and Ala-21 (dashed arrow).
Gln-26 in IL-8 is replaced by leucine, it remains active (Clark-
Lewis et al., 1994), as does NAP-2 when Met-26 is replaced by
leucine (Castor et al., 1990).
ELR Region-The amino-terminal residues Glu-22, Leu-23,
and especially Arg-24 have been identified in IL-8 as being
important for receptor binding (Hebert et al., 1991; Clark-
Lewis et al., 1991, 1993; Moser et al., 1993). This ELR se-
quence, which is conserved in the chemokines NAP-2, GROll',
and murine inflammatory protein-2 (Fig. 1), which compete
with IL-8, is necessary but not sufficient for binding to the two
classes of IL-8 receptors on neutrophils (Oppenheim et al.,
1991). For example, IL-8 binds tightly to both receptors,
whereas the other chemokines bind tightly to only the type II
receptor (Moser et al., 1991; Holmes et al., 1991; Murphy and
Tiffany, 1991). When the ELR sequence is introduced into PF4
and yIP-lO, the former acquires activity, but the latter does not
(Clark-Lewis et al., 1993). Besides the ELR motif, a compact
tertiary structure with intact disulfide bonds is needed (Peveri
et al., 1988; Van Damme et al., 1989) in addition to appropriate
residues at positions 22-43, 47-52, and 66 (IL-8 residues 4-22,
30-35, and 49) (Clark-Lewis et al., 1994).
The conformation of the amino-terminal ELR region is well
defined in every subunit of NAP-2 except subunit C (Fig. 4),
which lacks density for Ala-213 to Leu-23c. However, the par-
ticular structure adopted by an ELR region depends strongly
upon the local environment. The ELR regions of subunits A and
B have very different structures (Fig. 5) because they are
stabilized by different interactions: the former with a symme-
try-related NAP-2 tetramer and the latter with subunit D in its
own tetramer. Conversely, the ELR region of subunit D recip-
rocally interacts with subunit B in the same tetramer and
adopts a conformation similar to that seen in subunit B. Be-
cause of crystal packing and asymmetry in the NAP-2 tet-
ramer, neither interaction is accessible to the ELR region in
subunit C, which is consequently disordered. Clearly, the main
chains of the ELR regions exhibit unusual flexibility despite
being tethered to the core of the protein through disulfide
bridges at Cys-25 and Cys-27. Moreover, the side chain of
Arg-24b , which has no intra- or intermolecular contacts, exhib-
its two conformations, indicating that this critical residue in
receptor binding also has intrinsic conformational flexibility
(Fig. 5). At physiological concentrations, where NAP-2 probably
functions as a monomer (Rajarathnam et al., 1994; Schnitzel et
al., 1994; Yang et al., 1994), the ELR region would be uncon-
strained by intermolecular interactions, much like the case
with subunit C, and could adopt an extended conformation on
the receptor if necessary.
The positions of the ELR residues in the IL-8 crystal struc-
ture (Baldwin et al., 1991) match those in subunit B ofNAP-2
better than in subunit A or D. The C-a atoms of the two leucine
residues and the two arginine residues are separated by 3.65
and 1.11 A, respectively (Glu-22 is not defined in the IL-8
crystal structure). Although Leu-23b and Arg-24b in NAP-2 and
Leu-23 in the IL-8 crystal structure have no intermolecular
contacts, the side chain of Arg-24 in IL-8 forms three hydrogen
bonds with a symmetry-related molecule in the crystal. The
first five amino-terminal residues in the IL-8 NMR structure
are considered as being partially disordered due to a standard
deviation of 5 Ain the atomic positions of these residues (Clore
et al., 1990). In the bovine PF4 crystal structure, the amino-
terminal residues are disordered, and position 24, which is the
first residue defined by electron density in the structure, is a
GIn instead of Arg (St. Charles et al., 1989).
It has also been suggested that Glu-22 {E4) in IL-8 may form
a salt bridge with either Lys-40 {K23) or Lys-59 (K42) in the
adjacent monomer ofIL-8, but since neither lysine is critical for
receptor binding, it is more likely that Glu-22 interacts with
the receptor and not with the other subunit in the dimer
(Hebert et al., 1991). The equivalent residues in NAP-2 are
Gln-40 and Thr-59, so no ion pair is possible in our structure.
Ile-28 in IL-8 has also been shown to be sensitive to mutagen-
esis and important for receptor binding (Hebert et al., 1991).
The side chain of Ile-28, which occupies excellent electron den-
sity in our structure, has only one contact within 4.0 A (Lys-29
C-Il) and is sufficiently exposed to interact directly with the
receptor.
Activation ofNAP-2-{3-TG, CTAP-III, and PBP, which differ
from NAP-2 only in having an additional 11, 15, and 24 residues,
respectively, added to the amino terminus, are all inactive to-
ward the IL-8 receptors at physiological concentrations (Walz et
al., 1989). The longer isoforms, which predominate in quiescent
platelets, are converted to NAP-2 by cathepsin G, which cleaves
the Tyr-21-Ala-22 peptide bond and releases the activation pep-
tide. The system has strong positive feedback in that NAP-2
activates neutrophils, which release cathepsin G (Cohen et al.,
1992), which in turn activates platelets. Since a longer amino
terminus does not induce a detectable change in the secondary
structure of the NAP-2 portion (Yang et al., 1994), it is likely that
the extended amino-terminal chain inhibits by blocking access to
one or more of the sites on NAP-2 that bind the receptor. The
neural network method of Holley and Karplus (1989) predicts a
turn of a-helix in the activation peptide consisting of Glu-12 to
Asp-16. This predicted structure places two acidic groups on the
same side of the helix, where they could interact with a positive
residue such as Arg-24 (Fig. 6).
The activation peptide present in {3-thromboglobulin (resi-
dues 10-20) has a provocative similarity to the amino-terminal
extracellular domain of the IL-8 receptor in having a high
concentration of acidic residues. Clubb et al. (1994) have pro-
posed from NMR data that the receptor peptide, which has nine
acidic residues among 40 positions for the type I receptor and
12 acidic residues among 49 for the type II receptor, binds to
IL-8 in the cleft between residues 30-38 (residues 12-21) and
the third strand of {.:l-sheet, where it could interact with a
cluster of basic residues. NAP-2 has three conserved residues
whose basic side chains project into this region, namely Lys-29,
Lys-37, and Arg-64.
Another similarity between the activation peptide in {.:l-TG
and the amino-terminal extracellular domain ofthe IL-8 type II
receptor is the prediction that residues 43-46 (ESLE) of the
receptor have the same helical structure, with two acidic
groups on the same side of the helix, as predicted for the
activation peptide. Moreover, residues 43-46 are in the one
stretch of the receptor sequence that exhibits significant simi-
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FIG. 7. Comparison of NAP-2 with
IL-8 and PF4. The a-carbon backbone of
subunit B of NAP-2 (thick lines) is com-
pared with that of IL-8 (A, thin lines;
x-ray structure) and human PF4 (B,
thin lines). The superpositions were calcu-
lated with residues 23-86 and 24-85,
respectively.
larity to the sequence of the activation peptide. The predicted
a-helical region in the receptor peptide lies near the first trans-
membrane a-helix in the proposed receptor structure (LaRosa
et al., 1992). Therefore, cleavage of J3-TG or a longer precursor
into NAP-2 not only would remove the residues blocking the
ELR sequence or other subsite, but would also allow the newly
exposed amino terminus of NAP-2 to approach the receptor
membrane closely and to interact with the putative a-helix in
the receptor sequence. The type I receptor, for which NAP-2
has a much lower affinity, is less similar in sequence to the
activation peptide and cannot have a helix with two acidic
residues on the same side. These predictions raise the intrigu-
ing possibility that the activation peptide mimics, at least in
part, the receptor interactions with NAP-2.
However, extensive alanine scanning of the IL-8 type I re-
ceptor sequence did not find any critical acidic residues among
the 40 residues of the amino-terminal extracellular domain
(Hebert et al., 1993; Leong et al., 1994). Replacement ofThr-18,
Pro-21, or Tyr-27 reduced significantly the binding constant for
IL-8 but not the mobilization of calcium, while replacement of
Cys-30, which is near the predicted helical region in the type II
receptor (as the conserved Cys-40), abolished both binding and
transduction. An additional 19 residues in the second, third,
and fourth extracellular domains were also shown to be in-
volved in IL-8 binding.
Comparison with Other Chemokine Structures-Together,
the crystal structures of NAP-2 and IL-8 identify some of the
nuances of the interaction between the chemokines and their
receptors. Two types of human neutrophil receptors for IL-8,
whose sequences are 77% identical, have been separately
cloned and expressed in mammalian cells (Moser et al., 1991;
Holmes et al., 1991; Murphy and Tiffany, 1991; Cerretti et al.,
1993). IL-8 activates both type I and II receptors while NAP-2,
which has 44% identity to IL-8, activates only the type II
receptors at equivalent concentrations, although at high con-
centration, it can completely displace bound IL-8 from the
surface of neutrophils (Petersen et al., 1994). In contrast, PF4
and -yIP-I0 activate neither receptor (Clark-Lewis et al., 1993,
1994). However, when residues 22-43, 47-52, and 66 in -yIP-I0
are replaced by the equivalent residues in IL-8 {residues 4-22,
30-35, and 491, the hybrid -yIP-I0 is as potent as IL-8 in
activating neutrophils (Clark-Lewis et al., 1994), which sug-
gests that positions 22-43, 47-52, and 66 in the CXC chemo-
kine sequence define the binding sitets) for both types ofrecep-
tor. Of course, it is still possible that other residues, which by
chance are identical in IL-8 and -yIP-lO, are also critical parts
of an extended binding site. However, outside of the three
subsites defined above, -yIP-I0 has only nine residues that are
identical to those in IL-8, and of these, only one is on the
surface in the IL-8 structure and accessible to a receptor
molecule.
Consequently, the explanation for IL-8 binding strongly to
both receptors but NAP-2 only binding tightly to the type II
receptor probably lies in the structural or chemical differences
in these three subsites. An upper limit for structural differ-
ences attributable to error and thermal motion can be calcu-
lated from the differences among the independently deter-
mined structures of the four NAP-2 subunits. The maximum
average C-a displacement relative to subunit B is 0.58 ± 0.28
Afor subsite I (residues 25-39 in subunit C), 1.09 ± 0.58 Afor
subsite II (residues 47-52 in subunit C), and 0.42 Afor subsite
III (residue 66 in subunit A). The amino-terminal ELR resi-
dues, which have large differences among some subunits as
discussed above, were omitted from these calculations.
By these criteria, the structure of NAP-2, as measured by
C-a positions relative to those of IL-8, exceeds the average
displacement by more than two standard deviations at posi-
tions 28 and 32-37 (Figs. 7 and 8) in subsite I, but at no
positions in subsite II or III. Although four of the seven resi-
dues at positions 32-37 are identical between IL-8 and NAP-2,
the structural differences are not surprising given the insertion
of Pro-33A in the sequence of IL-8. This site is the strongest
candidate for a structural difference excluding NAP-2 from
binding to the type I receptor.
Gly-48 and Pro-49 are critical for maximal binding of IL-8 to
its receptors (Clark-Lewis et al., 1994). Ifthese two residues in
IL-8 are switched or replaced by the equivalent residues in
-yIP-I0 (Ser-48 and Gln-49), binding is decreased 170-fold




FIG. 8. Deviations in C-a atom posi-
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positionsare shownfor NAP-2 overlapped
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FIG. 9. Comparison of the positively
charged side chains in the carboxyl-
terminal a-helix of NAP·2 and recom-
binant human PF4. The main chain at-
omsfor residues 75-85 and the side chain
atoms for !ysines 76, 77,81, and 82 in the
carboxyl-terminal a-helix of subunit B of
NAP-2 (thick lines) are shown in stereo
overlapped with the equivalent main
chain atoms and the side chain atoms for
residues 76, 77, 80, and 81 ofrecombinant
human PF4 (thin lines).
(Clark-Lewis et aZ., 1994). Although residues 48 and 49 in
NAP-2 are shifted by over 1.8 Afrom those in IL-8, shifts of
similar magnitude are seen among the NAP-2 subunits them-
selves. Because the chemokine structure is unusually flexible
in this region, any effects of structural differences must be
secondary to those caused by differences in sequence, namely
the presence of Thr-49 in NAP-2 instead of the proline found in
IL-8.
Surprisingly, mutagenesis of His-50 in IL-8 {H33l does not
affect activity, in contrast to its immediate neighbors, Gly-48
{G31} and Pro-49 {P32} (Clark-Lewis et aZ., 1994), although its
side chain is near the ELR region in the IL-8 NMR structure,
where it forms a hydrogen bond with Gln-26. A possible expla-
nation lies in the NAP-2 structure, which shows that the His-50
side chain has two conformations available, one of which is
buried. The side chains of His-50a (Xl = -54°) and His-bu, (Xl
= -48°) are solvent-accessible (side chain-accessible surface
areas of 56.7 and 64.6 A2, respectively) and near the ELR
region. His-fill; forms two hydrogen bonds within the ELR
segment (between the nitrogen of Arg-24a and the NE2 of
His-fin; and between the NDI of His-fiu, and the oxygen of
Glu-22a ) . The only other residue in the NAP-2 tetramer, ex-
eluding contacts due to crystal packing, with side chain atoms
within 4.0 Aof the ELR region is Thr-49a , which contacts the
side chain of Leu-23a . The side chain of His-Sf), is in a similar
conformation and within 3.5 Aof Arg-24c, but the angles of the
possible hydrogen bonds exceed the limits.
The side chain of His-50b (Xl = 63°) adopts a different con-
formation than that of His-fitl; and His-fiu, in that it points
away from the ELR region and is buried within the core of the
protein (solvent-accessible surface area of 3.9 A2). Specifically,
the NDI of His-50b forms an intersubunit hydrogen bond with
the carbonyl oxygen of Gly-63 d . The His-50 side chains in the
IL-8 x-ray structure and in three subunits of the PF4 tetramer
have an orientation similar to that of His-fitl., in the NAP-2
structure. The side chain conformation of His-50d lies between
that of His-50a , His-50c, and His-50b , with a X,l angle of -47°
and a solvent-accessible surface area of 41.9 A2 • His-50d lies
within 5.7 Aof the ELR region, but does not have contacts with
it. However, the NE2 of His-50d does form an intersubunit
hydrogen bond with the carbonyl oxygen of Asp-62b •
The third region with significant structural differences
among the CXC chemokines involves the a-helices at the car-
boxyl terminus of each subunit. In the crystal structures of
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NAP-2 and IL-8 and the NMR structure of IL-8, the pair of
antiparallel helices in the AB dimers (and CD dimers in
NAP-2) traverse the extended l3-sheets at an angle of approx-
imately 58°. The distance between the helices in each pair is 8.5
A for the crystal structures ofNAP-2 and IL-8, but 10 and 11 A
for the crystal structure of bovine PF4 and the NMR structure
of IL-8, respectively. Moreover, the helices of bovine and hu-
man PF4 are translated approximately 1.8 A with respect to
the helices in NAP-2 and IL-8 (Fig. 7B), which accounts for the
larger than average root mean square deviation between the
helical regions (Table 11).
Mutagenesis studies have shown that residues 52-72 in IL-8,
which include the carboxyl-terminal a-helix, are not directly
involved in receptor binding or activation (Hebert et al., 1991;
Clark-Lewis et aZ., 1991), but playa structural role instead.
The helix has also been implicated in the binding of heparin to
PF4 (Hardin and Cohen, 1976) and of heparin and heparan
sulfate to IL-8 (Webb et al., 1993). The binding of heparan
sulfate to IL-8 increases the rate of chemotaxis by 3-4-fold and
enhances Ca2 + release. Heparin had a similar effect on Ca2 +
response, but did not enhance chemotaxis. The binding of IL-8
to heparan sulfate is abolished with the removal of residues
69-90 (Webb et al., 1993). Although the heparin-Ils-S complex
has a different overall charge and perhaps a slightly different
conformation, the increased activity of IL-8 could also be due to
the stabilization of IL-8 oligomers when the anionic polysac-
charide binds across or between the pairs of helices.
Although no crystal structure exists of the complex between
heparin and any chemokine, Stuckey et aZ. (1992) have pro-
posed a model of heparin binding to bovine PF4 that predicts
that seven basic residues, namely His-35, Lys-37, Lys-61, Lys-
76, Lys-77, Lys-80, and Lys-81, interact with the negatively
charged heparin chain that runs perpendicular to a pair of
a-helices in a dimer. NAP-2 has Lys-80 replaced by glutamine
and a new lysine at position 82, which dramatically changes
the arrangement of positive charges in the helices (Fig. 9) as
proposed by Lawler (1981). When NAP-2 is overlapped with
bovine PF4 in the model of Stuckey et al. (1992), Lys-76 and
Lys-82 do not interact with the heparin acidic groups, which
would explain the weaker heparin binding ofNAP-2 relative to
PF4. Platelet basic protein, the precursor ofNAP-2, elutes from
a heparin-Sepharose column with 0.6-0.7 M NaCI (Holt and
Niewiaroski, 1985), which is comparable to IL-8, which elutes
from heparin columns at 0.5 M NaCI (Van Damme et aZ., 1989).
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